Overview

Study in Healthy Adults Evaluating PF-07202954

Status:
Recruiting
Trial end date:
2022-03-08
Target enrollment:
Participant gender:
Summary
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer